StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reissued a “neutral” rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.
Check Out Our Latest Report on TCON
TRACON Pharmaceuticals Stock Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The business had revenue of $0.06 million during the quarter.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
See Also
- Five stocks we like better than TRACON Pharmaceuticals
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is Forex and How Does it Work?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- The 3 Best Blue-Chip Stocks to Buy Now
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.